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 Abstract 
Germ cell tumors (GCT) are curable cancers, but 10-15% of patients with metastatic disease fail cisplatin-
based first-line therapy. While therapeutic options have increased for various other cancers no thera-
peutic targets have emerged in cisplatin-refractory GCT. L1 cell adhesion molecule (L1-CAM) is common-
ly expressed in human malignancies and therefore a potential target, however its expression in GCT has 
not been studied so far. The aim of our study was to describe the expression of L1-CAM in a large series 
of testicular GCT. Immunohistochemistry was used to study L1-CAM expression in 325 testicular GCT, 
including 94 mixed GCT. L1-CAM expression was found in 38% of seminomas, 50% of yolk sac tumors, 
19% of teratomas, 50% of choriocarcinomas, 67% of embryonal carcinoma. L1-CAM was expressed in 
45% of germ cell neoplasias in situ but not in normal tissue. This common L1-CAM expression in testicu-
lar GCT might serve as an immunotherapeutic target in the future. INTRODUCTION 
In 2015, an estimated number of 8,430 new cases of GCT will be diagnosed in the United States [1]. Alt-
hough GCTs show a high sensitivity to cisplatin-based chemotherapy, 10-15% of patients fail first-line 
chemotherapy and 3-5% of all GCT patients will eventually die of their disease [2]. Despite a response 
rate above 95% to cisplatin based chemotherapy, the search for new treatment strategies remains 
worthwhile in accordance to reduce treatment toxicity and offer therapeutic options in non-responding 
patients [3-5]. Various tumors have been described to express L1-CAM including lung carcinoma, glio-
mas, melanoma, renal, ovarian, endometrial and colon carcinoma [6]. L1-CAM is associated with tumor 
cell dissemination via the regulation of pro-metastatic MMP-2 and MMP-9 in solid and non-solid tumors 
[7] as well as in brain metastases[8]. L1-CAM is involved in epithelial to mesenchymal transition 
(EMT)[9]. In various malignancies there is evidence showing that expression of L1-CAM is associated with 
a subset of highly aggressive tumors with adverse clinical outcome and might serve as a therapeutic tar-
get[10]. We aimed to investigate the expression of L1-CAM in the different GCT subtypes. 
MATERIALS AND METHODS 
The construction of the tissue micro array (TMA)  was described before [9]. L1-CAM immunohistochemis-
try (IHC) was performed using the monoclonal antibody anti-L1-CAM (clone 14.10, directed to the ecto-
domain, 1:200). The antibody was generated as described previously [11] and was tested on a multi tis-
sue TMA for the appropriate dilution. Peripheral neuronal tissue served as internal positive control for 
L1-CAM staining. Sertoli cells and Leydig cells were negative for L1-Cam. Two experienced surgical 
pathologists (PKB, VT) evaluated the L1-CAM stained TMA. Samples were dichotomized into positive 
versus negative. The threshold for positivity was defined at 5% of cells with a moderate or strong stain-
ing. The expression patterns were separately analyzed for each tumor component, GCNIS and normal 
tissue. The study was approved by the local ethics committee (reference number KEK StV. 25-2008). RESULTS 
The series included a total of 207 seminomas, 4 spermatocytic tumours, 19 pure embryonal carcinomas, 
1 pure mature teratoma and 94 mixed GCT. Mixed germ cell tumors included the following components: 
seminoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma and teratoma (49 with and 45 with-
out a seminomatous component).  
The individual tumor components consisted of 253 seminomas, 89 embryonal carcinomas, 52 yolk sac 
tumors, 53 teratomas, 10 choriocarcinomas. In addition, we included non-tumorous testicular tissue 
from 20 tumor patients and GCNIS from 20 patients.  
L1-CAM IHC staining showed an exclusively membranous staining pattern in GCTs with moderate to 
strong intensity. In seminoma, IHC staining of L1-CAM showed a predominantly heterogeneous mem-
branous pattern and 95 cases (38%) were L1-CAM positive (see table and figure 1). 
Tissue types Negative Positive Positive cases in % 
Normal testis (n=20) 20 0 0% 
Intratubular germ cell neoplasia (n=20) 11 9 45% 
Seminoma (n=253) 158 95 38% 
Choriocarcinoma (n=10) 5 5 50% 
Yolk sack tumor (n=52) 26 26 50% 
Embryonal carcinoma (n=89) 29 60 67% 
Teratoma (n=53) 43 10 19% 
 
Table 1 L1-CAM expression in non-neoplastic and neoplastic testicular tissue 
 
 The yolk sac tumors with microcystic, glandular, solid and spindle cell growth patterns showed a hetero-
geneous expression of L1-CAM in 26 cases (50%). The glandular components were positive in a L1-CAM 
staining whereas areas with stromal or spindle cell differentiation were negative. The results of L1-CAM 
staining in teratoma components were very heterogeneous depending on the tissue types found in the 
teratoma. Ten cases (19%) showed L1-CAM positive structures, e.g. glands with a membranous pattern. 
Stromal components as well as chondrocytes were L1-CAM negative. Five (50%) choriocarcinoma cases 
expressed L1-CAM. The expression was more restricted to the syncytiotrophoblastic giant cells whereas 
the mononuclear component was predominantly negative. Interestingly, syncytiotrophoblastic giant cells 
were also positive when scattered in a seminomatous tissue component. In embryonal carcinoma 59 
cases (63%) were positive with an intense and homogenous pattern. Normal testicular tissue was L1-
CAM negative whereas IGCNU showed a strong expression of L1-CAM in 45% of all cases.  DISCUSSION 
Recently, L1-CAM has emerged as a potential therapeutic target due to its expression on many solid tu-
mors, and only limited expression on normal tissues[6]. In-vitro and in-vivo studies showed efficacy and 
safety of L1-CAM targeting antibodies by acting via antibody-dependent cellular cytotoxicity (ADCC) or by 
being labeled with radionuclides[12-23]. In a humanized transgenic mouse model of L1-CAM no adverse 
effects were observed after injection of ant-L1-CAM antibodies [24]. A first in human phase I trial was 
published by Park et al showed no adverse effects and some objective response after infusing autologous 
CE7R/HyTK+ CD8+ cytolytic T-lymphocytes [20]. However, it cannot be concluded from this study, if the 
response was due to the L1-CAM therapy or the subsequent salvage therapies. 
We observed that L1-CAM expression is markedly enhanced in most GCTs, in 45% of GCNIS but not in 
normal tissue. As typical for a retrospective study, this investigation is limited by potential biases, such as 
patient selection and bias of core punching. 
To our knowledge this is the first publication describing L1-CAM expression in GCTs. We conclude that 
the frequent expression of L1-CAM in testicular seminomas and non-seminomas indicates that L1-CAM 
could be a promising new therapeutic target in testicular cancer that warrants further functional studies 
and potentially investigation in clinical trials in the future. Because L1-CAM was never expressed on 
normal but frequently on cancer cells, further investigation should elaborate the role for L1-CAM as a 
new "neoplastic" germ cell tumor marker. 
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Figure Labelling 
Figure 1. L1 cell adhesion molecule (L1-CAM)staining in several tumor components: Classic seminoma 
with heterogeneous membranous (A); Embryonal carcinoma with typical homogenous and intense 
membranous staining pattern (B); Yolk sac tumor with weak heterogeneous membranous staining (C); 
choriocarcinoma with strong membrane staining in dispersed tumor cells, predominantly multinucleated 
giant cells (D); teratoma with heterogeneous membranous staining (E); strong staining in the basal part 
of the tubuli in carcinoma-in-situ (CIS) germ cells (F) 
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